Sixty-nine
of the interviewed 100 women received chemotherapy, 23 endocrine
therapy and 41 monoclonal antibodies. In total,
64 % used CAM, 48 % used at least one substance-bound
CAM. In 17 out of those 48 cases (35 %), interactions were unlikely,
whereas they were probable in 14 patients (29 %).
Thus, a third of all patients in this study were in danger of
interactions.
More than half of all CAM users and three quarters of
users of substance-bound CAM are at risk of interactions. This number
is independent of whether the patient is taking
chemotherapy, endocrine therapy or antibodies.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.